H
Hasan Rajabi
Researcher at Harvard University
Publications - 69
Citations - 3401
Hasan Rajabi is an academic researcher from Harvard University. The author has contributed to research in topics: MUC1 & Gene silencing. The author has an hindex of 34, co-authored 67 publications receiving 2640 citations. Previous affiliations of Hasan Rajabi include Dana Corporation & Northwestern University.
Papers
More filters
Journal ArticleDOI
MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signalling
Rehan Ahmad,Deepak Raina,Vishal Trivedi,Jian Ren,Hasan Rajabi,Surender Kharbanda,Donald Kufe +6 more
TL;DR: In this paper, it was shown that MUC1 is associated with constitutive activation of NF-κB p65 in human carcinoma cells, and that the activation of IKKβ is dependent on TAK1 and TAB2.
Journal ArticleDOI
Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Deepak Raina,Michio Kosugi,Rehan Ahmad,Govind Panchamoorthy,Hasan Rajabi,Maroof Alam,Takeshi Shimamura,Geoffrey I. Shapiro,Jeffrey G. Supko,Surender Kharbanda,Donald Kufe +10 more
TL;DR: It is shown that inhibition of MUC1-C with cell-penetrating peptides blocks this interaction with PI3K p85 and suppresses constitutive phosphorylation of Akt and its downstream effector, mTOR.
Journal ArticleDOI
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
Takahiro Maeda,Masayuki Hiraki,Caining Jin,Hasan Rajabi,Ashujit Tagde,Maroof Alam,Audrey Bouillez,Xiufeng Hu,Yozo Suzuki,Masaaki Miyo,Tsuyoshi Hata,Kunihiko Hinohara,Donald Kufe +12 more
TL;DR: It is reported that genetic or pharmacological targeting of the oncogenic M UC1 subunit MUC1-C is sufficient to suppress PD-L1 expression in TNBC cells, and this finding offers a rationale to target MUC-C as a novel immunotherapeutic approach for TNBC treatment.
Journal ArticleDOI
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia
Athalia Rachel Pyzer,Dina Stroopinsky,Hasan Rajabi,Abigail Washington,Ashujit Tagde,Maxwell D. Coll,Jacqueline Fung,Mary Paty Bryant,Leandra Cole,Kristen Palmer,Poorvi Somaiya,Rebecca Karp Leaf,Myrna Nahas,Arie Apel,Salvia Jain,Malgorzata McMasters,Lourdes M. Mendez,James D. Levine,Robin Joyce,Jon E. Arnason,Pier Paolo Pandolfi,Donald Kufe,Jacalyn Rosenblatt,David Avigan +23 more
TL;DR: It is demonstrated that AML EVs are taken-up myeloid progenitor cells, resulting in the selective proliferation of MDSCs in comparison with functionally competent antigen-presenting cells, and the microRNA miR34a acts as the regulatory mechanism by which MUC1 drives c-myc expression in AML cells and EVs.
Journal ArticleDOI
Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Masanori Hasegawa,Hidekazu Takahashi,Hidekazu Takahashi,Hasan Rajabi,Maroof Alam,Yozo Suzuki,Li Yin,Ashujit Tagde,Takahiro Maeda,Masayuki Hiraki,Vikas P. Sukhatme,Donald Kufe +11 more
TL;DR: It is shown that silencing MUC1-C is associated with decreases in xCT expression in TNBC cells and that targeting this novel MUC2-C/xCT pathway could represent a potential therapeutic approach for promoting TNBC cell death.